Sentence examples for matched primary samples from inspiring English sources

Interestingly, in our series, vascular density was significantly lower in recurrent tumours compared with their matched primary samples.

Recurrent tumours showed significantly lower vascular density (P=0.0004) compared with their matched primary samples (Supplementary Figure 3A).

Vascular density of the early recurrent tumours was significantly lower compared with their matched primary samples in our series.

Early local recurrence specimens demonstrated a significantly increased infiltration of CD11b+ myeloid cells (P=0.0097) but decreased CD31-positive vessel density (P=0.0004) compared with their matched primary samples.

In contrast, examination of the recurrence samples in 10 of the 12 patients with early recurrence demonstrated a significant increase in the number of CD11b+ cells (P=0.0097) compared with their matched primary samples.

In contrast, examination of the recurrence samples demonstrated a significant increase in the number of CD11b+ cells that occurred in 10 out of the 12 patients compared with their matched primary samples.

Representative examples of tumours with low and high stromal CD68 and CD163 expression are shown in Figure 2. Furthermore, we examined the expression of TAMs in available biopsy samples from 12 patients that developed early local recurrence and compared it with their matched primary tumour samples.

We did not find a significant difference in either CD68+ or CD163+ cell infiltration between the recurrences and their matched primary tumour samples.

To further confirm that PRL-3 expression is specific of tumour cells, microdissection was performed in a set of six matched primary tumour/LM samples.

While we did not find correlation between clinicopathological data such as hormone receptor status, triple-negative phenotype or LVI in metastatic tissues that were identified in the matched primary tumor samples, we did find correlation between high FAK expression in primary tumors and metastatic tissues.

In all, 17 out of 24 (71%) metastatic PTCs were found to have stronger immunostaining than their matched primary PTC samples: 14 with local regional lymph node metastasis and three with distant metastases (one metastasised to the nose 8 years after treatment, and the other two metastasised to the lung and brain frontal lobe, respectively at the time of diagnosis).